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Purpose or Objective: The aim of this study was to assess 
the 6-months dysphagia-free survival, improvement in 
swallowing function, complication rate, and overall survival 
in patients with incurable esophageal cancer treated with 
palliative radiotherapy. 
 
Material and Methods: We retrospectively reviewed data 
from 139 patients (median age 72 years) with 
advanced/recurrent incurable esophageal cancer, who were 
referred to 3 German radiation oncology centers for 
palliative radiotherapy between 1994 and 2014. Radiotherapy 
consisted of external beam radiotherapy (EBRT) with 30 - 
40.5 Gy/2.5 - 3 Gy per fraction, brachytherapy alone (BT) 
with 15 - 25 Gy/5 - 7Gy per fraction/weekly and EBRT + BT 
(30 - 40.5 Gy plus 10 - 14 Gy with BT) in 65, 46, and 28 
patients, respectively. Dysphagia-free survival (Dy-PFS) was 
defined as the time to worsening of dysphagia for at least 
one point, a new loco-regional failure or death of any cause. 
 
Results: Median follow-up time was 6 months (range 0.57-6.0 
months). Subjective symptom relief was achieved in 72 % of 
patients with median response duration of 5 months. The 1-
year survival rate was 30%. The 6-months Dy-PFS time for the 
whole group was 73 ± 4%. The 6-months Dy-PFS was 90 ± 4% 
after EBRT, 92 ± 5% after EBRT + BT and 37 ± 7% after BT, 
respectively (p<0.001). Five patients lived for more than 2 
years, all of them were treated with EBRT ± BT. Ulceration, 
fistula and stricture developed in 3, 6 and 7 patients, 
respectively.  
 
Conclusion: Radiotherapy leads to symptom improvement in 
the majority of patients with advanced incurable esophageal 
cancer. The present results favor EBRT ± BT over BT alone. 
Due to the retrospective nature of this study, imbalances in 
baseline characteristics might have contributed to this 
finding, and further trials appear necessary. 
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Purpose or Objective: To evaluate patterns of recurrence 
and identifyits related factors among patients with Stage 
pT3N0M0 thoracic esophageal squmous cell carcinoma (ESCC) 
after two-field esophagectomy. 
 
Material and Methods: 249 patients with Stage pT3N0M0 
thoracic ESCC after radical esophagectomy administered in 
2008 and 2009 were identified and enrolled into this study. 
There were 171 men and 78 women; median age was 60 
years-old(33 – 78). The distributions of tumor sites were 39 in 
upper-, 166 in middle- and 44 in lower-thoracic segment. The 
median lesion length was 5 cm with a range of 2 to 12 cm. 
Among them, there were 98 patients received with surgery 
alone, 20 with radiotherapy (RT), 110 with chemotherapy 
alone (CT), and 21 with radiotherapy and chemotherapy 
(CRT). Their locoregional recurrence (LR) of tumor and 
distant metastasis (DM) as the endpoints were analyzed. 
 
Results: The overall recurrence rates was 43.4% (108), LR 
occurred in 23.7%, DM in 10.4%, and combined recurrence in 
9.2%, respectively. For 82 patients with LR, there were 
15.9%(13/82) recurred in supraclavicular, 87.8% (72/82) in 
mediastinum, 9.8% (8/82) in upper abdomen. The rate of LR 
in upper-mediastinal and supraclavicular was 80%(66/82). 
The rate of LR were 53.8% in upper-, 33.1% in middle- and 
13.6% in low-thoracic ESCC, respectively. Multivariate 
analysis indicate, site of lesion was the independent factors 
for total recurrence and LR. 
 
Conclusion: The recurrence rate was very high in pT3N0M0 
thoracic ESCC patients, LR was the mainly cause and most of 
it was occurred in supraclavicular and upper-mediastinum. 
Site of lesion was the mainly factor effected on LR. PORT 
should be strongly suggest in upper- and recommend in 
middle-, but not in low-thoracic ESCC. 
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Purpose or Objective: Locoregional recurrence pattern after 
curative treatment for patients with esophageal cancer has 
changed since the introduction of preoperative 
chemoradiation as standard part of curative treatment. The 
aim of this study was to determine the outcome of salvage 
definitive chemoradiation (dCRT) for a locoregional 
recurrence outside previously irradiated areas.  
 
Material and Methods: We retrospectively reviewed 41 
patients treated between January 2005 and December 2014 
for locoregional recurrent esophageal cancer outside 
previously irradiated areas. All patients were treated with 
external beam radiotherapy (50.4 Gy in 28 fractions) 
combined with weekly concurrent paclitaxel and carboplatin. 
 
Results: The median follow up period was 30 months (range 
1.7-120 months). dCRT was completed according to protocol 
in 90%. The 1-, 3- and 5-year overall survival rate after 
treatment for recurrence was 74%, 35% and 30% respectively . 
The median local recurrence free survival (LRFS) and overall 
survival (OS) time was 27 and 22 months respectively. Median 
OS was 14.4 months for squamous cell carcinoma (SCC) and 
22.0 months for adenocarcinoma (AC) (p=0.81). Median 
survival after salvage dCRT for a lymph node recurrence was 
48 months versus 14 months for a recurrence at the 
anastomosis (p= 0.009). Sixteen patients (39%) developed a 
locoregional recurrence after salvage dCRT, 8 out of 20 SCC 
and 8 out of 21 AC patients. Only 2 LR after salvage dCRT 
were solely outfield. In 8 of the 16 LR patients there were 
synchronous distant metastasis (43%). 
 
Conclusion: Definitive chemoradiation is an effective 
treatment for recurrent esophageal cancer outside a 
previously irradiated area, and should be given with a 
curative intent. This holds true for recurrences of both 
squamous cell carcinoma and adenocarcinoma. Lymph node 
recurrences have a markedly better prognosis than 
recurrences at the anastomotic site. Locoregional failures 
after salvage treatment occur almost solely infield, at the 
site of the first recurrence. 
 
 
 
